Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Conquering Language Boundaries: Individual Accounts of Multilingualism - 2Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- 3Iranian strikes on Israel injure 11 and set chemical plant ablaze
- 4A company is trying to unlock a key to aging, in a long-overlooked body part
- 5Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- Novartis eyes more bolt-on acquisitions, CEO says
- Israel says it killed armed Hamas 'terrorists' in Gaza
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- Setbacks in Texas and elsewhere put Republicans' redistricting hopes in doubt as key deadlines loom
- These Cities Led Global Jet-Setting In 2025, According To New Data
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships
- Native Americans had dice and games of probability long before other cultures, study finds
- Dental, Vision, and Hearing Inclusion in Senior Protection.
